Interim Report July-September 2018
Clinical trials on track Stockholm, 14 November, 2018: Asarina Pharma AB releases its Interim Report for 1 July – 30 September, 2018.Third Quarter Highlights · Asarina’s Phase IIB study in PMDD (Premenstrual Dysphoric Disorder) progressed during the third quarter with a steady increase in the recruitment of patients. The company expects as previously communicated to have topline results before year-end 2019. · During the third quarter, the Company intensified its preparations for the phase IIA study in menstrual migraine. The study will be initiated in the second quarter of 2019